IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
Top Cited Papers
Open Access
- 15 April 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 122 (11), 1580-1589
- https://doi.org/10.1038/s41416-020-0814-x
Abstract
Isocitrate dehydrogenase (IDH) enzymes catalyse the oxidative decarboxylation of isocitrate and therefore play key roles in the Krebs cycle and cellular homoeostasis. Major advances in cancer genetics over the past decade have revealed that the genes encoding IDHs are frequently mutated in a variety of human malignancies, including gliomas, acute myeloid leukaemia, cholangiocarcinoma, chondrosarcoma and thyroid carcinoma. A series of seminal studies further elucidated the biological impact of the IDH mutation and uncovered the potential role of IDH mutants in oncogenesis. Notably, the neomorphic activity of the IDH mutants establishes distinctive patterns in cancer metabolism, epigenetic shift and therapy resistance. Novel molecular targeting approaches have been developed to improve the efficacy of therapeutics against IDH-mutated cancers. Here we provide an overview of the latest findings in IDH-mutated human malignancies, with a focus on glioma, discussing unique biological signatures and proceedings in translational research.Keywords
This publication has 125 references indexed in Scilit:
- Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activationNature, 2012
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotypeNature, 2012
- IDH mutation impairs histone demethylation and results in a block to cell differentiationNature, 2012
- Identification of additional IDH mutations associated with oncometabolite R(−)-2-hydroxyglutarate productionOncogene, 2011
- Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditionsBritish Journal of Cancer, 2011
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent DioxygenasesCancer Cell, 2011
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of GliomaCancer Cell, 2010
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-HydroxyglutarateCancer Cell, 2010
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- IDH1andIDH2Mutations in GliomasNew England Journal of Medicine, 2009